How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

203 results for

Clinical Index of Stable Febrile Neutropenia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation

might result in more febrile neutropenia (15% versus 2%, P=0.001). Evidence from uncontrolled phase II studies appeared to complement the RCT findings but did not compensate for the lack of RCTs. These studies were compromised by potential biases, clinical diversity, statistical heterogeneity and a lack of precision. Cost information Four economic evaluations were included in the review. When comparing the cost-effectiveness of vinorelbine, paclitaxel and docetaxel, one study found vinorelbine (...) examined in the included trials. Funding NHS R&D Health Technology Assessment (HTA) programme, project number 00/15/03. Bibliographic details Lewis R, Bagnall A M, King S, Woolacott N, Forbes C, Shirran L, Duffy S, Kleijnen J, ter Riet G, Riemsma R. The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation. Health Technology Assessment 2002; 6(14): 1-269 Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH

2002 DARE.

202. Clinical practice guidelines for the management of early breast cancer

to I 298 6.2 cyclophosphamide, methotrexate and 5-fluoro- uracil (CMF) for both recurrence-free survival and overall survival at the increased risk of alopecia, cardiac toxicity and febrile neutropenia. 16.Dose intensity is important to outcome in II 311 6.2 adjuvant cytotoxic therapy, at least in dose ranges achievable without colony stimulating factor (CSF) support. 17.T reatment with high-dose chemotherapy outside II 314, 315 6.2 of clinical trials is not recommended. 18.Women should be fully (...) : AIHW (Cancer Series).12 Clinical practice guidelines for the management of early breast cancer Mortality Age-standardised rates have remained stable, at around 25–27 deaths per 100,000 woman-years between 1982 and 1996. 20 Survival The report Breast cancer survival in Australian women 1982–1994 showed that five-year relative survival in Australian women of all ages increased from 74.4 per cent in 1982–1987 to 78.9 per cent in 1988–1992. 21 Survival was best in women aged in their 40s and poorer

2001 Cancer Australia

203. Clinical practice guidelines for the management of advanced breast cancer

Clinical practice guidelines for the management of advanced breast cancer i Clinical practice guidelines for the management of advanced breast cancer Clinical practice guidelines for the management of advanced breast cancer Prepared by the iSource National Breast Cancer Centre Advanced Breast Cancer Working Group Endorsed January 2001ii Clinical practice guidelines for the management of advanced breast cancer © Commonwealth of Australia 2001 ISBN Print: 0642455457 Online: 0642455465 This work (...) Clinical practice guidelines for the management of advanced breast cancer has been endorsed without inclusion of a comparative economic analysis of the costs associated with their implementation. It is the understanding of the NHMRC that an up-to-date economic analysis will be included when the Clinical practice guidelines of the management of advanced breast cancer are next updated. This document is sold through AusInfo Government Info Bookshops at a price which covers the cost of printing

2000 Cancer Australia

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>